US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral ...

Autoimmune diseases, like multiple sclerosis result when the body's immune system starts to attack its own cells. Regulatory T cells, a subtype of T cells play a critical role in suppressing these ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB).

Researchers reveal how activating the Egr-1 gene can help alleviate autoimmune inflammation via Foxp3 expression Autoimmune ...

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect millions of people ...

Enhanced Genomics has formed a partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge to ...

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. The designation ...

Cis-regulatory elements (CREs)—including promoters, enhancers, silencers, and insulators—are critical non-coding DNA ...

In Say Hello to the Bad Guys: How Professional Wrestling’s New World Order Changed America, the ESPN reporter Marc Raimondi ...